Houston, Texas and Burlington, Ontario, October 6^th, 2022

RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage biotechnology company announced the arrangement with Portland Investment Counsel Inc. (“Portland”) to complete an equity round of $40 million of a Series A funding round. Radiomedix is committed to the advancement of a targeted alpha therapy (TAT) pipeline and diagnostic companion radiopharmaceuticals for rare and aggressive cancers.

The proceeds of the financing will be applied to developing RadioMedix’s flagship radiopharmaceutical AlphaMedix^TM, a lead-212 (Pb²¹²) labelled somatostatin analogue TAT agent for the treatment of metastatic or inoperable somatostatin expressing neuroendocrine tumors, in addition to other diagnostic and therapeutic (theranostic) radiopharmaceuticals that are under development by the Company to address needs in oncology.

Houston, TX and Plano, TX, Jan. 03, 2022

RadioMedix and Orano Med are pleased to announce the initiation of the Phase II clinical trial of AlphaMedix™ with the treatment of the first patient on December 21^st, 2021. This trial will evaluate the safety and effectiveness of ²¹²Pb-DOTAMTATE (AlphaMedix™) in Peptide Receptor Radionuclide Therapy (PRRT) of naive patients with somatostatin receptor-expressing neuroendocrine tumors (NET).

“The initiation of the Phase II trial is a significant milestone in the clinical development of our innovative targeted alpha-emitter radiotherapy and brings us one step closer to having this drug available for our patients”, said Ebrahim Delpassand, MD, Chairman and Chief Executive Officer of RadioMedix. “Targeted alpha therapy (TAT) with ²¹²Pb-DOTAMTATE has been shown to be well-tolerated and preliminary efficacy results are highly promising.

November 17, 2021

RadioMedix awarded $2.0 M NCI SBIR direct-to-Phase II grant to develop drug for targeted alpha-emitter therapy

RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Phase Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute at the US National Institutes of Health . The grant supports Phase I/II clinical development of innovative alpha-emitter labeled peptide, AlphaMedix^TM, for therapy of somatostatin receptor positive neuroendocrine tumors.

September 2^nd, 2021

RadioMedix, Inc. is a key manufacturer and supplier of cGMP radiotherapeutics for late-stage clinical trials and commercial production.

RadioMedix will produce cGMP drug product for Rhenium-186 NanoLiposome (¹⁸⁶RNL) and may extend to future products under the RNL platform.

AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it has entered into an agreement with RadioMedix, Inc. (RadioMedix) for the commercial production of the Company’s radiopharmaceuticals.

The AIM-HI Accelerator Fund just announced 10 semi-finalists for the 2021 Women’s Venture Competition! These oncology companies have been selected from among an exceptional pool of applications submitted globally by women scientist-entrepreneurs. Decision making was led by a selection committee comprised of world-class key opinion leaders, life sciences industry experts, investors, and entrepreneurs.

Houston-Texas August 2^nd, 2021

Excel Diagnostics and Nuclear Oncology Center (EDNOC), a premier Diagnostic Imaging and Radioligand Therapy   center in Houston, Texas announces approval of its physicians sponsored Investigational New Drug (IND) application for providing Targeted Alpha Therapy (TAT) with ²²⁵Ac-PSMA I&T for metastatic Castration Resistant Prostate Cancer (mCRPC). “We are glad to be able to make this game changing drug available to our patients suffering from mCRPC. Excel Diagnostics and Nuclear Oncology Center has been a pioneer in bringing new targeted Radioligand Therapies such as Lu-177 DOTATATE, and Lu-177 PSMA to serve our patients in the United States. The addition of ²²⁵Ac-PSMA I&T is in continuation of our mission to address unmet needs in the field of Nuclear Oncology” said Dr. Ebrahim Delpassand, Chairman and Medical Director of EDNOC and co-Principle Investigator of the trial. “PSMA is an established prostate cancer target. Highly encouraging results have been reported by using Targeted Alpha Therapy (TAT) Radiopharmaceuticals in conditions such as neuroendocrine, prostate, or hematological malignancies. These breakthroughs have brought significant amount of hope to our patients suffering from different types of advanced cancers.” Said Dr. Rodolfo Nuñez, Director of Nuclear medicine Department at EDNOC and Co-Principle Investigator of the trial.

MARSEILLE, France & HOUSTON--(BUSINESS WIRE)--Vect-Horus and RadioMedix are pleased to announce the FDA clearance of exploratory Investigational New Drug (eIND) application to evaluate ⁶⁸Ga-RMX-VH for the detection and mapping of Low Density Lipoprotein Receptor (LDLR) overexpressed in Glioblastoma Multiforme (GBM). The Phase 1 exploratory study sponsored by RadioMedix will start enrollment upon IRB « Internal Review Board » approval. The study will investigate safety, dosimetry and distribution of ⁶⁸Ga-RMX-VH in patients with primary or recurrent GBM. The eIND clinical study will proceed in Excel Diagnostic and Nuclear Oncology Center (Houston, TX).

ROCKVILLE, MD - The National Foundation for Cancer Research (NFCR) announced winners of the 2021 Salisbury Award Competition for Entrepreneurial Translational Research, selected from among eight semi-finalists after pitch presentations in front of a judging committee consisting of prominent cancer research scientists, clinicians, early-stage investors and business leaders.

The semi-finalists were determined earlier in the spring based upon applications from among academic laboratories or early-stage companies advancing promising experimental cancer therapeutic, diagnostic, detection and vaccine innovations.

The newest FDA-approved PET imaging agent for neuroendocrine tumors — Detectnet^TM (copper Cu 64 Dotate injection) — is now included in the National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines in Oncology – Neuroendocrine and Adrenal Tumors, version 1.2021. The announcement was made by RadioMedix Inc. and its commercial partner, Curium, on May 5. Detectnet is a positron emission tomography (PET) agent indicated for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults.

Houston (TX), Jan. 04, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. Houston-based clinical-stage radiopharmaceutical company is proud to announce that the company was selected for the 2020 TechConnect Innovation Award. The annual TechConnect Business Innovation Awards program recognizes the top 15% of submitted technologies as ranked by the selection committee in multiple categories from the Energy, Nanomaterials, Health and Medicine, AI, Robotics, and others. The Summit is co-organized by SBIR/STTR Innovation Program and co-located with Defense Innovation Summit.

Houston, TX, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Radiomedix a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer, announced the appointment of Dr. Ferey Faridian as a member of its Board of Directors.

“It is an honor to join the world-class team at Radiomedix to guide in the areas of strategy and finance at a time when the company is at the brink of creating new treatment modalities in neuroendocrine cancers, said Faridian.”

Garching/Munich, Germany, and Houston, Texas, U.S., December 08, 2020: ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and RadioMedix Inc., a clinical stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has issued the Drug Master File (DMF no. 34938) for ITM’s next generation Germanium-68/Gallium-68 (⁶⁸Ge/⁶⁸Ga) Generator, distributed under the brand name GeGant®.The DMF will allow parties interested in developing new drugs for the U.S. market to refer to the DMF and use GeGant® in clinical tests for radiopharmaceuticals and in other settings.

ST. LOUIS, Dec. 09, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that the Centers for Medicare & Medicaid Services (CMS) has granted Detectnet Transitional Pass-Through Status (code C9068) effective January 1, 2021. The descriptor for Detectnet will be: Copper Cu-64, dotatate, diagnostic, 1 millicurie. C9068 will be used to bill Detectnet for Medicare patients seen in the hospital outpatient department.

Houston, TX, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Radiomedix a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer, announced the appointment of Dr. Ferey Faridian as a member of its Board of Directors.

“It is an honor to join the world-class team at Radiomedix to guide in the areas of strategy and finance at a time when the company is at the brink of creating new treatment modalities in neuroendocrine cancers, said Faridian.”

Houston, TX and St. Louis, MO, Sept. 07, 2020 (GLOBE NEWSWIRE) -RadioMedix Inc. and its commercial partner Curium announced today that Detectnet^TM (copper Cu 64 dotatate injection) was approved by the U.S. Food and Drug Administration (FDA). Detectnet is a positron emission tomography (PET) agent indicated for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. Curium expects to launch Detectnet immediately with doses available through various nuclear pharmacies or directly from Curium.  

ITM’s long-term partner RadioMedix is producing and distributing GeGant^® for the U.S. market

GARCHING, Germany & MUNICH & HOUSTON--(BUSINESS WIRE)--ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and RadioMedix Inc., a clinical stage biotechnology company, announced today that ITM has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for ITM’s next generation Germanium-68/Gallium-68 (⁶⁸Ge/⁶⁸Ga) Generator, which is manufactured at the RadioMedix Spica Center in Houston, Texas, U.S. and distributed under the brand name GeGant^®.

Houston, TX, USA and Garching, Germany. RadioMedix, and OncoBeta today announced the execution of an exclusive distribution agreement for the next generation of W/Re-188 generators in the U.S. and Canada.   The OncoBeta® Tungsten (Wolfram)-188/Rhenium-188

Houston, Jan. 02, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization Accelerator Program (CAP) by the National Institute of Health (NIH) SBIR/STTR

Houston and St Louis, Jan. 07, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that the New Drug Application for copper Cu 64 dotatate injection was filed with the U.S.